Media stories about CTD (OTCMKTS:CTDH) have been trending extremely negative this week, InfoTrie Sentiment reports. InfoTrie scores the sentiment of press coverage by reviewing more than 6,000 blog and news sources in real time. The firm ranks coverage of companies on a scale of negative five to five, with scores closest to five being the most favorable. CTD earned a media sentiment score of -4.57 on their scale. InfoTrie also gave news stories about the biotechnology company an news buzz score of 8 out of 10, indicating that recent press coverage is very likely to have an effect on the company’s share price in the immediate future.
OTCMKTS CTDH remained flat at $$0.37 during trading on Friday. The business has a fifty day moving average of $0.43. CTD has a 1 year low of $0.30 and a 1 year high of $1.18.
CTD (OTCMKTS:CTDH) last announced its quarterly earnings results on Wednesday, May 15th. The biotechnology company reported ($0.02) earnings per share (EPS) for the quarter. The business had revenue of $0.22 million for the quarter. CTD had a negative return on equity of 1,504.86% and a negative net margin of 516.52%.
CTD Company Profile
CTD Holdings, Inc, a biotechnology company, develops cyclodextrin-based products for the treatment of diseases. Its lead drug candidate is Trappsol Cyclo, an orphan drug for the treatment of Niemann-Pick Type C disease. The company also sells cyclodextrins and related products to the pharmaceutical, nutritional, and other industries, primarily for use in diagnostics and specialty drugs.
Featured Article: Equal Weight Rating
Receive News & Ratings for CTD Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CTD and related companies with MarketBeat.com's FREE daily email newsletter.